drugset / Trial / NCT00708201

A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy

NCT00708201

Phase 4 Completed 280 enrolled Merck & Co., Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is being conducted to determine whether alvimopan can accelerate recovery of gastrointestinal function following radical cystectomy when compared with a placebo. Secondary objectives of the study are: * to evaluate the effect of alvimopan on hospital length of stay * to evaluate the effect of alvimopan on prespecified postoperative ileus (POI)-related morbidities * to evaluate the overall and cardiovascular safety of alvimopan

Timeline

Start
2009-03
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Alvimopan Small molecule 12 mg Oral

Indications